CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
What You Need to Know
Key takeaway #1
Medicare will pay less for 340B drugs next year. Starting in 2027, CMS will lower payments from the average sales price plus 6% to the average sales price minus 28%, a smaller cut than originally proposed.
Key takeaway #2
CMS will make two separate adjustments to payments for non-drug services. It will increase those payment rates by 7.5% to balance the new drug-payment cuts, while separately applying a 2% annual reduction to recover extra payments made under the earlier 340B policy.
Client Alert | 3 min read | 11.17.26
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
CMS also finalized a smaller annual conversion-factor reduction for the separate, historical 340B remedy offset:
- 340B drug payment: Proposed ASP minus 33.4%; finalized ASP minus 28%.
- Budget-neutral increase in the conversion factor for non-drug items and services: proposed 8.44%; finalized 7.50%.
- Separate historical 340B remedy offset: proposed increasing the annual reduction from 0.5% to 3%; finalized increasing it from 0.5% to 2%, beginning in CY 2027.
These are two distinct budget-neutrality mechanisms. One redistributes the savings from the new drug-payment reduction, while the other recovers past increases in non-drug payments associated with the 2018–2022 policy. They should not be conflated. The rules address these mechanisms separately. The proposed rule expressly sought comment on ASP minus 28% as an alternative. At that stage, CMS estimated that alternative would reduce OPPS drug payments by $4.68 billion and support an 8.14% conversion-factor increase. The final figures for the adopted alternative were instead $4.65 billion and 7.50%.
Payments for 340B drugs and the corresponding budget-neutral increase
Separate conversion-factor reduction for the historical 340B remedy
This adjustment recovers approximately $7.8 billion in increased non-drug payments made during CYs 2018–2022, after CMS made lump-sum remedy payments for the historical drug-payment reductions. The existing policy began with a 0.5% annual reduction in CY 2026.
What this means
Given the existing litigation over the payment for 340B drugs that arose after CMS attempted to reduce payments, managed care organization legal departments should monitor for any challenges to this new rule and coordinate with the appropriate internal stakeholders to ensure any rate changes resulting from this new rule are implemented with consideration of that historical litigation landscape.
Contacts

- Washington, D.C.
- D | +1.202.624.2683
Insights
Client Alert | 9 min read | 11.17.26
Priorities and Prospects for AI Legislation in the New Congress
Concerns about artificial intelligence played a seminal role in the midterm congressional elections. One exit poll found that 56% of voters said that AI and data centers were a “crucial or major factor” in their vote for Congress, and voters passed over 40 ballot measures to restrict data centers.
Client Alert | 8 min read | 11.16.26
OCC’s AI Examiner Framework: How Banks’ AI Use Can Trigger Legal Liability and Supervisory Exposure
Client Alert | 3 min read | 11.13.26
Massachusetts Trade Secret Preliminary Injunctions: Prove the Harm, Tailor the Relief
Client Alert | 1 min read | 11.12.26
SBA Announces Doubling Veteran Contracting Target to 10% for FY 2027, but Questions Remain







